WuXi Biologics (Cayman) Inc.
WXIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $18,675,371 | $17,034,255 | $15,268,660 | $10,290,050 |
| % Growth | 9.6% | 11.6% | 48.4% | – |
| Cost of Goods Sold | $11,024,551 | $10,206,354 | $8,544,646 | $5,461,153 |
| Gross Profit | $7,650,820 | $6,827,901 | $6,724,014 | $4,828,897 |
| % Margin | 41% | 40.1% | 44% | 46.9% |
| R&D Expenses | $766,443 | $792,577 | $682,818 | $501,583 |
| G&A Expenses | $1,673,514 | $1,495,352 | $1,269,592 | $875,932 |
| SG&A Expenses | $2,147,115 | $1,789,361 | $1,432,505 | $1,000,579 |
| Sales & Mktg Exp. | $473,601 | $294,009 | $162,913 | $124,647 |
| Other Operating Expenses | -$236,542 | -$204,234 | $266,769 | $138,624 |
| Operating Expenses | $2,677,016 | $2,377,704 | $2,382,092 | $1,640,786 |
| Operating Income | $4,973,804 | $4,450,197 | $4,341,922 | $3,188,111 |
| % Margin | 26.6% | 26.1% | 28.4% | 31% |
| Other Income/Exp. Net | -$139,406 | -$276,394 | $1,015,849 | $805,008 |
| Pre-Tax Income | $4,834,398 | $4,173,803 | $5,357,771 | $3,993,119 |
| Tax Expense | $889,027 | $603,179 | $807,865 | $484,538 |
| Net Income | $3,356,081 | $3,399,729 | $4,420,286 | $3,388,478 |
| % Margin | 18% | 20% | 29% | 32.9% |
| EPS | 0.82 | 0.81 | 1.06 | 0.81 |
| % Growth | 1.2% | -23.6% | 30.9% | – |
| EPS Diluted | 0.78 | 0.77 | 1.01 | 0.77 |
| Weighted Avg Shares Out | 4,082,094 | 4,163,543 | 4,172,736 | 4,400,626 |
| Weighted Avg Shares Out Dil | 4,227,165 | 4,348,874 | 4,375,908 | 4,421,797 |
| Supplemental Information | – | – | – | – |
| Interest Income | $350,366 | $219,178 | $107,475 | $58,026 |
| Interest Expense | $157,587 | $158,488 | $64,382 | $39,191 |
| Depreciation & Amortization | $1,437,054 | $1,169,376 | $800,674 | $481,783 |
| EBITDA | $6,429,039 | $5,501,667 | $6,222,827 | $4,514,093 |
| % Margin | 34.4% | 32.3% | 40.8% | 43.9% |